Select Bibliography

Filter by any of these (after searching):

Iveson, Timothy

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 4 items

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

André, Thierry , Meyerhardt, Jeffrey , Iveson, Timothy ... - - Lancet Oncol - 2020

Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80702

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017

Abstract - Secondary-not-in-original - Comprehensive - GI - CALGB-80702

Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration

Shields, Anthony F. , Ou, Fang-Shu , Paul, James ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80702

Overall survival (OS) of comparing 3 vs 6 months of adjuvant (adjuv) oxaliplatin-based therapy for patients (pts) with stage III colon cancer (CC): Updated results from the IDEA (International Duration Evaluation of Adjuv chemotherapy) collaboration

Sobrero, Alberto F. , Thierry, Andre , Meyerhardt, Jeffrey A. ... - ASCO - J Clin Oncol - 2020

Abstract - Secondary - Primary - GI - CALGB-80702